U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H22FN3O3
Molecular Weight 407.4375
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Catequentinib

SMILES

COC1=CC2=C(OC3=C(F)C4=C(NC(C)=C4)C=C3)C=CN=C2C=C1OCC5(N)CC5

InChI

InChIKey=KSMZEXLVHXZPEF-UHFFFAOYSA-N
InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3

HIDE SMILES / InChI
Molecular Formula C23H22FN3O3
Molecular Weight 407.4375
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGFβ), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3). Anlotibib is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661) which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Phase III development is underway for the treatment of thyroid cancer, gastric cancer, leiomyosarcoma; non-small cell lung cancer; synovial sarcoma; thyroid cancer etc.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
Antagonist
2849
 0.2 nM [IC50]
Antagonist
2849
 1.0 nM [IC50]
Antagonist
2849
Antagonist
2849
 7.7 null [pIC50]
Antagonist
2849
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase III
665
Unknown

Approved Use

Unknown
Primary
Phase III
665
Unknown

Approved Use

Unknown
Primary
Phase III
665
Unknown

Approved Use

Unknown
Primary
Phase III
665
Unknown

Approved Use

Unknown
Primary
Phase III
665
Unknown

Approved Use

Unknown
Primary
Phase III
665
Unknown

Approved Use

Unknown
Primary
Phase III
665
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5.8 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27716285/
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ANLOTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
5.8 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27716285/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ANLOTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
10.5 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27716285/
12 mg single, oral
dose: 12 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ANLOTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
15.8 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27716285/
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ANLOTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
687 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27716285/
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ANLOTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
562 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27716285/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ANLOTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1066 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27716285/
12 mg single, oral
dose: 12 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ANLOTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1585 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27716285/
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ANLOTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
102 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27716285/
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ANLOTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
95 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27716285/
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ANLOTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
116 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27716285/
12 mg single, oral
dose: 12 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ANLOTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
98 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27716285/
16 mg single, oral
dose: 16 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ANLOTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
7.9%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/29620050/
ANLOTINIB plasma
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Other AEs: Hemoptysis, Pneumonia...
Other AEs:
Hemoptysis (7 patients)
Pneumonia (3 patients)
Venous thromboembolism (3 patients)
Interstitial lung disease (2 patients)
Pneumothorax (2 patients)
Proteinuria (2 patients)
Respiratory failure (2 patients)
Hypertension (1 pt)
Abdominal pain (1 pt)
Gastrointestinal hemorrhage (1 pt)
Hypophosphatemia (1 pt)
Oral mucositis (1 pt)
Fatigue (1 pt)
Hand foot syndrome (1 pt)
Low density lipoprotein increased (1 pt)
Appendicitis (1 pt)
Hand-foot syndrome (7 patients)
Hypertension (3 patients)
Hypertriglyceridemia (2 patients)
Diarrhea (1 pt)
Liver dysfunction (1 pt)
Anorexia (2 patients)
Oral mucositis (2 patients)
Arrhythmia (2 patients)
Fatigue (1 pt)
Dyspnea (1 pt)
Hypertension (all grades, 67.7%)
Fatigue (all grades, 52%)
Anorexia (all grades, 45.9%)
Hypertriglyceridemia (all grades, 44.6%)
Hand-foot syndrome (all grades, 43.9%)
Hypercholesteremia (all grades, 41.8%)
Cough (all grades, 41.5%)
Diarrhea (all grades, 35.4%)
Low density lipoprotein increased (all grades, 31.3%)
Proteinuria (all grades, 28.9%)
Pharyngalgia (all grades, 28.2%)
Blood bilirubin increased (all grades, 26.2%)
Hyponatremia (all grades, 23.5%)
Weight loss (all grades, 23.1%)
Mucositis oral (all grades, 23.1%)
Dysphonia (all grades, 23.1%)
Low density lipoprotein increased (all grades, 21.1%)
Hemoptysis (all grades, 20.4%)
Hematuria (all grades, 15%)
Upper respiratory infection (all grades, 12.6%)
Urinary tract infection (all grades, 11.6%)
Headache (all grades, 11.2%)
Decreased platelet count (all grades, 10.5%)
Hypertension (grade 3-4, 13.6%)
Fatigue (grade 3-4, 1 pt)
Anorexia (grade 3-4, 3 patients)
Hypertriglyceridemia (grade 3-4, 9 patients)
Hand-foot syndrome (grade 3-4, 11 patient)
Cough (grade 3-4, 3 patients)
Diarrhea (grade 3-4, 3 patients)
GGT increased (grade 3-4, 16 patients)
Proteinuria (grade 3-4, 7 patients)
Pharyngalgia (grade 3-4, 2 patients)
Pharyngalgia (grade 3-4, 5 patients)
Hyponatremia (grade 3-4, 24 patients)
Mucositis oral (grade 3-4, 3 patients)
Dysphonia (grade 3-4, 3 patients)
GGT elevation (grade 3-4, 2 patients)
Hemoptysis (grade 3-4, 9 patients)
Decreased platelet count (grade 3-4, 3 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Other AEs: Fatigue, Hypertension...
Other AEs:
Fatigue (all grades, 57%)
Hypertension (all grades, 54%)
Decreased appetite (all grades, 43%)
Hypothyroidism (all grades, 36%)
Palmar-plantar erythrodysesthesia (all grades, 27%)
Proteinuria (all grades, 26%)
Weight loss (all grades, 19%)
Diarrhea (all grades, 17%)
Leukopenia (all grades, 17%)
Aspartate aminotransferase increased (all grades, 17%)
Hypercholesterolemia (all grades, 15%)
Hypertriglyceridemia (all grades, 14%)
Gamma-glutamyltransferase increased (all grades, 14%)
Alanine aminotransferase increased (all grades, 14%)
Dysphonia (all grades, 14%)
Low density lipoprotein increased (all grades, 13%)
Lymphocytopenia (all grades, 13%)
Oropharyngeal pain (all grades, 12%)
Abdominal pain (all grades, 12%)
Globulin urine present (all grades, 11%)
Neutrophil count decreased (all grades, 11%)
Rash (all grades, 10%)
Nausea (all grades, 10%)
Hyperglycemia (all grades, 5%)
Insomnia (all grades, 1 pt)
Fatigue (grade 3, 2%)
Hypertension (grade 3, 16%)
Decreased appetite (grade 3, 6%)
Hypothyroidism (grade 3, 1 pt)
Palmar-plantar erythrodysesthesia (grade 3, 2 patients)
Proteinuria (grade 3, 1 pt)
Electrocardiogram QTc interval prolonged (grade 3, 1 pt)
Weight loss (grade 3, 3 patients)
Electrocardiogram QTc interval prolonged (grade 3, 2 patients)
Gamma-glutamyltransferase increased (grade 3, 3 patients)
Alanine aminotransferase increased (grade 3, 1 pt)
Increased low density lipoprotein (grade 3, 1 pt)
Lymphocytopenia (grade 3, 2 patients)
Oropharyngeal pain (grade 4, 1 pt)
death (grade 5, 3 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Appendicitis 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Diarrhea 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Dyspnea 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Fatigue 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Fatigue 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Gastrointestinal hemorrhage 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Hand foot syndrome 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Hypertension 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Hypophosphatemia 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Liver dysfunction 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Low density lipoprotein increased 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Oral mucositis 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Anorexia 2 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Arrhythmia 2 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Hypertriglyceridemia 2 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Interstitial lung disease 2 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Oral mucositis 2 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Pneumothorax 2 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Proteinuria 2 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Respiratory failure 2 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Hypertension 3 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Pneumonia 3 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Venous thromboembolism 3 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Hand-foot syndrome 7 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Hemoptysis 7 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Decreased platelet count all grades, 10.5%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Headache all grades, 11.2%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Urinary tract infection all grades, 11.6%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Upper respiratory infection all grades, 12.6%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Hematuria all grades, 15%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Hemoptysis all grades, 20.4%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Low density lipoprotein increased all grades, 21.1%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Dysphonia all grades, 23.1%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Mucositis oral all grades, 23.1%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Weight loss all grades, 23.1%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Hyponatremia all grades, 23.5%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Blood bilirubin increased all grades, 26.2%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Pharyngalgia all grades, 28.2%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Proteinuria all grades, 28.9%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Low density lipoprotein increased all grades, 31.3%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Diarrhea all grades, 35.4%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Cough all grades, 41.5%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Hypercholesteremia all grades, 41.8%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Hand-foot syndrome all grades, 43.9%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Hypertriglyceridemia all grades, 44.6%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Anorexia all grades, 45.9%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Fatigue all grades, 52%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Hypertension all grades, 67.7%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Fatigue grade 3-4, 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Hand-foot syndrome grade 3-4, 11 patient
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Hypertension grade 3-4, 13.6%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
GGT increased grade 3-4, 16 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
GGT elevation grade 3-4, 2 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Pharyngalgia grade 3-4, 2 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Hyponatremia grade 3-4, 24 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Anorexia grade 3-4, 3 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Cough grade 3-4, 3 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Decreased platelet count grade 3-4, 3 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Diarrhea grade 3-4, 3 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Dysphonia grade 3-4, 3 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Mucositis oral grade 3-4, 3 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Pharyngalgia grade 3-4, 5 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Proteinuria grade 3-4, 7 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Hemoptysis grade 3-4, 9 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Hypertriglyceridemia grade 3-4, 9 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/30666799/
Insomnia all grades, 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Nausea all grades, 10%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Rash all grades, 10%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Globulin urine present all grades, 11%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Neutrophil count decreased all grades, 11%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Abdominal pain all grades, 12%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Oropharyngeal pain all grades, 12%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Low density lipoprotein increased all grades, 13%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Lymphocytopenia all grades, 13%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Alanine aminotransferase increased all grades, 14%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Dysphonia all grades, 14%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Gamma-glutamyltransferase increased all grades, 14%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Hypertriglyceridemia all grades, 14%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Hypercholesterolemia all grades, 15%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Aspartate aminotransferase increased all grades, 17%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Diarrhea all grades, 17%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Leukopenia all grades, 17%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Weight loss all grades, 19%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Proteinuria all grades, 26%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Palmar-plantar erythrodysesthesia all grades, 27%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Hypothyroidism all grades, 36%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Decreased appetite all grades, 43%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Hyperglycemia all grades, 5%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Hypertension all grades, 54%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Fatigue all grades, 57%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Alanine aminotransferase increased grade 3, 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Electrocardiogram QTc interval prolonged grade 3, 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Hypothyroidism grade 3, 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Increased low density lipoprotein grade 3, 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Proteinuria grade 3, 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Hypertension grade 3, 16%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Electrocardiogram QTc interval prolonged grade 3, 2 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Lymphocytopenia grade 3, 2 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Palmar-plantar erythrodysesthesia grade 3, 2 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Fatigue grade 3, 2%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Gamma-glutamyltransferase increased grade 3, 3 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Weight loss grade 3, 3 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Decreased appetite grade 3, 6%
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
Oropharyngeal pain grade 4, 1 pt
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
death grade 5, 3 patients
12 mg 1 times / day multiple, oral
Studied dose
Dose: 12 mg, 1 times / day
Route: oral
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/33586360/
PubMed

PubMed

TitleDatePubMed
Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model.
2018-01
Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors.
2018
Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.
2016-10-04
Patents

Patents

US2016326138
2
US2017182027
2
US8148532
2
WO2008112407
2

Sample Use Guides

In Vivo Use Guide
Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
Route of Administration: Oral
In Vitro Use Guide
AN3CA cells appeared the most sensitive to AL3818 with an IC50 value of 84 nM. The other cell lines were approximately 28- to 550-fold less sensitive to AL3818. HEC1B had an IC50 value of 46 uM, and MFE296 cells were sensitive to AL3818, with an IC50 value of 2.9 uM compared with 3.2, 28.9, 29, and 40 uM for Ishikawa, MFE280, KLE, and HEC1A, respectively.
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:10:25 GMT 2025
Edited
by admin
on Mon Mar 31 21:10:25 GMT 2025
Record UNII
GKF8S4C432
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ANLOTINIB
Preferred Name English
Catequentinib
INN   USAN  
Official Name English
CATEQUENTINIB [USAN]
Common Name English
1-[({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl}oxy)methyl]cyclopropan-1-amine
Systematic Name English
Catequentinib [WHO-DD]
Common Name English
ALTN
Common Name English
AL3818
Code English
AL-3818
Code English
catequentinib [INN]
Common Name English
Cyclopropanamine, 1-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinolinyl]oxy]methyl]-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Mon Mar 31 21:10:25 GMT 2025 , Edited by admin on Mon Mar 31 21:10:25 GMT 2025
FDA ORPHAN DRUG 576017
Created by admin on Mon Mar 31 21:10:25 GMT 2025 , Edited by admin on Mon Mar 31 21:10:25 GMT 2025
NCI_THESAURUS C1742
Created by admin on Mon Mar 31 21:10:25 GMT 2025 , Edited by admin on Mon Mar 31 21:10:25 GMT 2025
Code System Code Type Description
DRUG BANK
DB11885
Created by admin on Mon Mar 31 21:10:25 GMT 2025 , Edited by admin on Mon Mar 31 21:10:25 GMT 2025
PRIMARY
EVMPD
SUB192810
Created by admin on Mon Mar 31 21:10:25 GMT 2025 , Edited by admin on Mon Mar 31 21:10:25 GMT 2025
PRIMARY
NCI_THESAURUS
C138997
Created by admin on Mon Mar 31 21:10:25 GMT 2025 , Edited by admin on Mon Mar 31 21:10:25 GMT 2025
PRIMARY
SMS_ID
100000177425
Created by admin on Mon Mar 31 21:10:25 GMT 2025 , Edited by admin on Mon Mar 31 21:10:25 GMT 2025
PRIMARY
FDA UNII
GKF8S4C432
Created by admin on Mon Mar 31 21:10:25 GMT 2025 , Edited by admin on Mon Mar 31 21:10:25 GMT 2025
PRIMARY
MANUFACTURER PRODUCT INFORMATION
ANLOTINIB
Created by admin on Mon Mar 31 21:10:25 GMT 2025 , Edited by admin on Mon Mar 31 21:10:25 GMT 2025
PRIMARY Anlotinib (AL3818) - MedKoo CAT NO.: 206058Description: Anlotinib, alos known as AL3818, is a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, anlotininib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus). (Last update: 7/2/2015). Synonym: AL3818, AL-3818, AL 3818, Anlotinib - IUPAC/Chemical Name: NONE
USAN
LM-10
Created by admin on Mon Mar 31 21:10:25 GMT 2025 , Edited by admin on Mon Mar 31 21:10:25 GMT 2025
PRIMARY
CAS
1058156-90-3
Created by admin on Mon Mar 31 21:10:25 GMT 2025 , Edited by admin on Mon Mar 31 21:10:25 GMT 2025
PRIMARY
ChEMBL
CHEMBL3545021
Created by admin on Mon Mar 31 21:10:25 GMT 2025 , Edited by admin on Mon Mar 31 21:10:25 GMT 2025
PRIMARY
PUBCHEM
25017411
Created by admin on Mon Mar 31 21:10:25 GMT 2025 , Edited by admin on Mon Mar 31 21:10:25 GMT 2025
PRIMARY
INN
11077
Created by admin on Mon Mar 31 21:10:25 GMT 2025 , Edited by admin on Mon Mar 31 21:10:25 GMT 2025
PRIMARY
Related Record Type Details
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 3
TARGET -> INHIBITOR
Structure of Catequentinib Hydrochloride
SALT/SOLVATE -> PARENT
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2
TARGET -> INHIBITOR
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1
TARGET -> INHIBITOR
Related Record Type Details
Structure of Catequentinib
ACTIVE MOIETY
Results: Dose-limiting toxicities (DLT) at the 10mg/d for consecutive 4 weeks group was grade 3 hypertension, and significant accumulation of anlotinib was observed. For 2 weeks on/1 week off group, DLT were grade 3 hypertension and grade 3 fatigue at the dose of 16 mg/d, the maximum-tolerated doses (MTD) was 12mg/d, the plasma concentration of anlotinib was well controlled. Anlotinib reached its maximum plasma concentration with Tmax of 411 h after orally administration at 10, 12, or 16 mg/subject. Then it eliminated slowly with t1/2of 64136 h and MRT of 124167 h. 20 patients of the 21 patients at the dose of 12mg/d (2 weeks on/1 week off) were assessable for efficacy, 3 patients had a partial response(include renal cancer(n = 2), and soft tissue tumor),14 patients had stable disease(include medullary carcinoma of thyroid, NSCLC, colon cancer, melanoma, thymic carcinoma, and adenoid cystic carcinoma), with 9 patients lasting > 72 weeks. Official Title: A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics Purpose: Anlotibib (ALTN) is a kind of innovative medicines approved by State Food and Drug AdministrationSFDA which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. ALTN is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2 and VEGFR3. It has the obvious resistance to new angiogenesis. Drug: Anlotinib(Primary); Indication: Renal cell carcinoma; Focus: Therapeutic Use; Sponsor: Chia Tai Tianqing Pharmaceutical Group; Most Recent Events: 25 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016., 25 Apr 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016., 22 Oct 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966